key: cord-0851100-r5uwqdaq
authors: Lai, Michele; La Rocca, Veronica; Amato, Rachele; Iacono, Elena; Filipponi, Carolina; Catelli, Elisa; Bogani, Lucia; Fonnesu, Rossella; Lottini, Giulia; De Carli, Alessandro; Mengozzi, Alessandro; Masi, Stefano; Quaranta, Paola; Spezia, Pietro Giorgio; Freer, Giulia; Lenzi, Paola; Fornai, Francesco; Piomelli, Daniele; Pistello, Mauro
title: N-acylethanolamine acid amide hydrolase is a novel target for drugs against SARS-CoV-2 and Zika virus
date: 2022-02-09
journal: bioRxiv
DOI: 10.1101/2022.02.08.479661
sha: a1fb04f91e12d151014ee8d9b69425ec551ca8e2
doc_id: 851100
cord_uid: r5uwqdaq

Several compounds have been tested against SARS-CoV-2; at present, COVID-19 treatments decrease the deleterious inflammatory response and acute lung injury. However, the best therapeutic response would be expected by combining anti-inflammatory properties, while concomitantly blocking viral replication. These combined effects should drastically reduce both infection rate and severe complications induced by novel SARS-CoV-2 variants. Therefore, we explored the antiviral potency of a class of anti-inflammatory compounds that inhibit the N-Acylethanolamine acid amidase (NAAA). This enzyme catalyzes the hydrolysis of palmitoylethanolamide (PEA), a bioactive lipid that mediates anti-inflammatory and analgesic activity through the activation of peroxisome proliferator receptor-α (PPAR-α). Similarly, this pathway is likely to be a significant target to impede viral replication since PPAR-α activation leads to dismantling of lipid droplets, where viral replication of Flaviviruses and Coronaviruses occurs. Here, we show that either genetic or pharmacological inhibition of the NAAA enzyme leads to five-fold reduction in the replication of both SARS-CoV-2 and ZIKV in various cell lines. Once NAAA enzyme is blocked, both ZIKV and SARS CoV-2 replication decrease, which parallels a sudden five-fold decrease in virion release. These effects induced by NAAA inhibition occurs concomitantly with stimulation of autophagy during infection. Remarkably, parallel antiviral and anti-inflammatory effects of NAAA antagonism were confirmed in ex-vivo experiments, within SARS-CoV-2 infected human PBMC cells, in which both viral genomes and TNF-α production drop by ~60%. It is known that macrophages contribute to viral spread, excessive inflammation and macrophage activation syndrome that NAAA inhibitors might prevent, reducing the macrophage-induced acute respiratory distress syndrome and subsequent death of COVID-19 patients.

To evaluate the effect of NAAA ablation on ZIKV replication, we infected A549 NAAA-/-clones at 189 a low MOI (0.1 MOI) of ZIKV, to avoid excessive cellular stress. It is well known that ZIKV enters 190 cells through the endocytic pathway only (24) (Figure 3a ), making it highly likely to co-localize with 191 NAAA during entry. 192 Figure 3b shows that A549 NAAA-/-cells exhibit a 5-fold reduction in the number of ZIKV plaque-193 forming units (PFU) compared to WT controls. Interestingly, we observed a moderate reduction of 194 ZIKV PFUs also in the NAAA heterozygotic A549 clone, where NAAA content is significantly 195 reduced but not abolished. Western Blot analysis confirmed a decrease in viral content since a fold reduction in ZIKV E intracellular protein content was measured in both A549 NAAA -/-and 197 NAAA +/-, compared to controls (Fig 3c-d) . Diminution of ZIKV E protein was enhanced by the 198 addition of Brefeldin-A, a drug that inhibits protein transport from the endoplasmic reticulum to the 199 Golgi complex, leading to intracellular ZIKV E accumulation (Fig 3c-d) . autophagy initiator ATG5 protein compared to controls (Fig 3c and e) . The induction of autophagy 207 was confirmed by measuring increased levels of LC3-II, which is the reference marker for 208 autophagosome maturation(27). In line with the previous result, LC3-II increases 3-fold in A549 209 NAAA-/-cells compared to controls, also during ZIKV infection (Fig 3f) . Finally, we measured 210 ZIKV genomes in supernatants of each cell type by qRT-PCR at 3h, 24h, and 48h post-infection. To NAAA-/-using anti-ZIKV E, ATG5 and LC3 I-II. Statistical analysis (d-f) was performed using One-220

Way Anova (p<0.01 *; p<0.001 **; p<0.0001 ***, α=0.05). Data are expressed as mean ± SD, N=4. 221 g) qRT-PCR quantification of ZIKV viral genomes performed on supernatants of A549, A549 222 NAAA+/-and A549 NAAA-/-, taken at different time-points (3h, 24h, 48h). Statistical analysis was 223 performed using One-Way Anova (p<0.01 *; p<0.001 **; p<0.0001 ***, α=0.05). Data are expressed 224 as mean ± SD, N=3. 225

Given the negative effect of NAAA reduction on ZIKV replication, we decided to test the antiviral 228 activity ARN077, a highly potent NAAA inhibitor (12) 

To assess if NAAA inhibitors might reproduce the same antiviral activity as NAAA ablation, we pre-309 treated Huh-7 cells with ARN077. As illustrated in Figure 6a , the NAAA inhibitor was administered 310 15 minutes before SARS-CoV-2 infection at the following concentrations: 0.1, 1, and 3 µM. Then, 311

we quantified SARS-CoV-2 genomes in the supernatants of Huh-7 by qRT-PCR (Fig. 6b) . Analysis 312 showed a 4-fold decrease of SARS-CoV-2 released virions in the presence of 1 µM ARN077. 313

Then, to assess whether NAAA inhibition might reduce the replication of SARS-CoV-2 variants, we 314 infected Huh-7 and Huh-7 NAAA-/-cells with two variants of concern, B.1.17 and B.1.617.2, known 315 as alpha and delta SARS-CoV-2 variants. As previously described, we infected the cells with 1 MOI 316 for 1h. Then the inoculum was removed and replaced with fresh medium, as schematically illustrated 317 in Figure 7a . Total RNA was extracted 48h after infection. As shown in Figure Prompted by the evidence that autophagy remains active in NAAA-/-cells during ZIKV and SARS-398

CoV-2 infection, we decided to dissect the PPAR-α pathway, which is activated by intracellularly 399 accumulated PEA. Since PEA is mainly degraded by NAAA, the absence of the latter causes PEA 400 accumulation; in line with this fact, we observed a 2-fold increase in PPAR-α expression in NAAA-401 /-cells, as measured by qRT-PCR (Fig. 10a) . This transcription factor, once activated by PEA, Finally, to evaluate vesicular pH variations, we performed A549 NAAA-/-live cell staining with 413 lysotracker dye, which increases fluorescence when pH decreases. Since the absence of NAAA is 414 likely to reduce palmitic acid within vesicles, this expected to produce a lower acidic environment, 415 as shown in Figure 10 g. Lysotracker assay revealed that both A549 +/-and -/-decrease the vesicular 416 acidity (Fig. 10 h-i) . 417 To probe the hypothesis that NAAA inhibition might dismantle LD needed for SARS-CoV-2 and 493 ZIKV replication, we measured transcription of PPAR-α by qRT-PCR. As shown in Figure 12b , A549 494 NAAA-/-cells exhibit increased transcription of genes involved in both mitochondrial and 495 peroxisomal β-oxidation; particularly, expression of LCAD and UCP2 were found 20 and 5 times 496 higher, respectively, in NAAA-/-than in WT cells. CPT1A and HADHa showed at least double the 497 expression than in WT counterparts, while ACOX was moderately but still significantly augmented. 498

To confirm increased β-oxidation at the lipid level, we stained LD in both A549 and A549 NAAA-/-499 with OilRed, expected to selectively mark LD intracellularly. Next, we took advantage of high content 500 confocal screening to count LD intracellular content three-dimensionally and objectively count them. 501

As shown in Figure 12c In the present work, we tested an antiviral drug candidate, which might exert two distinctive, seminal 526 functions: blocking viral replication and, at the same time, avoid excessive inflammatory response.. 527

For this reason, we investigated the antiviral effectiveness of NAAA inhibitors, well-established anti-528 inflammatory, and antinociceptive drugs(9). 529

Here, we show that SARS-CoV-2 and ZIKV reduce their replication by ~5 folds in different cell lines, 530 when the NAAA enzyme is inhibited using pharmacological or gene knock-out techniques. Once the 531 NAAA enzyme is blocked, ZIKV and SARS CoV-2 decrease their replication and, consequently, also 532 virion release drops abruptly by ~5 folds for both viruses. Surprisingly, we also found that NAAA 533 inhibition maintains autophagy active during infection, whereas both SARS-CoV-2 and ZIKV viruses 534 would hijack this pathway to boost their replication(25, 26, 34). A possible explanation for such an 535 effect is that, in the context of NAAA inhibition, neither virus replicates to a level sufficient to 536 counteract autophagic activation. Therefore, active autophagy contributes to viral clearance. This may 537 appears unexpected at first glance, since both SARS-CoV-2 and ZIKV viruses would hijack early 538 autophagy structures to boost their replication. It is possible that the stimulus induced by NAAA 539 inhibition to address autophagy-related membrane web towards lysosomal degradation counteract the 540 Our findings support the notion that host lipid metabolism and LDs are required for ZIKV and SARS-573

CoV-2 replication and suggest a novel potential strategy to interfere with viral replication in infected 574 cells by blocking NAAA is a potential novel strategy to counteract viral replication in cells infected 575 by at least ZIKV and SARS-CoV-2. 576

Together, these results highlight that a well-recognized anti-inflammatory agent can be also used as 577 an antiviral drug for the first time. Our data show that peripheral blood-derived human monocytes 578 infected with SARS-CoV-2 and treated with ARN077 exhibit decreased viral genome content 579 together with reduced production of TNF-α, compared to ARN077 untreated counterparts. This 580 finding supports the hypothesis that NAAA inhibition might be beneficial to treat COVID19 patients 581 and, hopefully, prevent aberrant macrophage activation during acute respiratory distress syndrome. 582

While NAAA was never studied as an antiviral target until now, its metabolite PEA has been used in 583 several placebo-controlled double-blind clinical trials on influenza and the common cold. Promising 584 results led to the clinical use of PEA under the brand name Impulsin in former Czechoslovakia (4). 585

As PEA plays a fundamental role as an anti-inflammatory lipid-modulating precursor, its activity is 586 counteracted by NAAA, which is abundant in macrophages and immune cells(40), the very cells 587 responsible for cytokine storm in severe COVID19. For this reason, while the antiviral activity of 588 PEA might not be durable, NAAA inhibition might have a longer-lasting efficacy and more potent 589 anti-inflammatory/antiviral activity, especially when administered in combination with PEA. 590

In summary, this work unveils a critical interaction between NAAA enzyme and viral replication, 591

proposing a new mechanism that ZIKV and SARS-CoV-2 use to hijack the host innate immune 

Germany) according to the 639 manufacturer's instructions. Total RNA (200 ng) was reverse-transcribed in cDNA and amplified by 640 using QuantiNova SYBR Green RT-PCR kit

Japan) according to the manufacturer's instructions. Then RNA was 643 reverse-transcribed and amplified using One Step PrimeScriptTM III RT-qPCR Mix kit

Primers and probes: ZIKV: F:5'-TGAGATCAACCACTGCAAGY-3', R: 5'-645 GCCTTATCTCCATTCCATACCA -3', Probe 5'-FAM-ATCGAGGAATGGTGCTGCAGGGA-646 BHQ1 -3. SARS-CoV-2: F: 5'-TCACCTATTTTAGCATGGCCTCT-3, R: 5'-647 CGTAGTGCAACAGGACTAAGC-3

PPAR-α : F: 5'-CTATCATTTGCTGTGGAGATCG-3', R: 5'-AAGATATCGTCCGGGTGGTT-3

Pex13: F:5'-GGGCCCCATTTTCCAATCCTG-3

Pex14: F:5'-GCCACGGCAGTGAAGTTTCTA-3

HADHA: F:5′-GCTAGACCGAGGACAGCAAC -3

UCP2: F: 5′ CACCAAGGGCTCTGAGCATG -3', R: 5′-TCTACAGGGGAGGCGATGAC -3' 658 ACOX1: F: 5′ TCCTGCCCACCTTGCTICAC -3′

LCAD: F: 5′-TGAGCGACTGGTGGGAGGAG -3, R: 5′-CACTGTCTGTAGGTGAGCAACTG

F: 5'AGGAGAAGCTGTGCTACGTC-3

Immunostaining and High-content confocal imaging

University of Pisa Grant: PRA_2020_37

Instrumentation Sharing-University of Pisa for the use of Operetta CLS imaging facility

M and PQ performed and analyzed the experiments

supervised analyses and provided reagents and resources

wrote the manuscript with input from all other authors

A systematic review of SARS-CoV-2 vaccine 759 candidates

Efficacy and Safety of the mRNA-761 1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the 763

BNT162b2 mRNA Covid-19 Vaccine

Palmitoylethanolamide: A Natural Body-Own Anti-765

Effective and Safe against Influenza and Common Cold

Anandamide 768 suppresses pain initiation through a peripheral endocannabinoid mechanism

A novel crosstalk within the 771 endocannabinoid system controls GABA transmission in the striatum

N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated 773 analgesia

Selective N-acylethanolamine-775 hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in 776 inflammation

NAAA): Structure, Function, and Inhibition

Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis

Molecular mechanism of activation of the 783 immunoregulatory amidase NAAA

Antinociceptive 785 effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models

A New Use for an Old Drug: Carmofur Attenuates 788

Lipopolysaccharide (LPS)-Induced Acute Lung Injury

analgesia through activation of peroxisome proliferator-activated receptor-alpha

Advances in the discovery of N-acylethanolamine acid amidase 793 inhibitors

Peroxisome proliferator-activated receptors, fatty acid oxidation, 795 steatohepatitis and hepatocarcinogenesis

Lipids and pathogenic flaviviruses: An intimate union

Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators

RNA recognition and signal transduction by RIG-I-like receptors

Metabolism of the Endocannabinoid Anandamide: Open Questions after 25

ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses

Acid ceramidase controls apoptosis 811 and increases autophagy in human melanoma cells treated with doxorubicin

ZIKA virus entry mechanisms in human cells

Zika Virus Infection: A 815

Possible Therapeutic Target to Counteract Viral Replication

Role of autophagy in Zika virus infection and pathogenesis

Detection of autophagy in tissue 819 by standard immunohistochemistry: possibilities and limitations

Macrophage-derived lipid agonists of PPAR-α as intrinsic 821 controllers of inflammation

Peroxisomal protein PEX13 823 functions in selective autophagy

Guidelines for the 825 use and interpretation of assays for monitoring autophagy

Isolation of the human peroxisomal 829 acyl-CoA oxidase gene: organization, promoter analysis, and chromosomal localization

ATGL Promotes Autophagy/Lipophagy via SIRT1 to 832

The SARS-CoV-2 protein ORF3a inhibits fusion of 834 autophagosomes with lysosomes

Multifaceted Role of AMPK in Viral Infections

Subversion of 838 cellular autophagosomal machinery by RNA viruses

Coxsackievirus can exploit LC3 in both 840 autophagy-dependent and -independent manners in vivo

lysosomal lipolysis is essential for alternative activation of macrophages

SARS-CoV-2 845 infection triggers profibrotic macrophage responses and lung fibrosis

New insights in mast cell modulation by 847 palmitoylethanolamide

A low-cost simple test for 849 weekly detection of Mycoplasma hyorhinis and arginini contaminations in cell cultures and viral 850 preparations

Immunohistochemical evidence 852 and ultrastructural compartmentalization of a new antioxidant enzyme in the rat substantia nigra

Mechanisms involved in the 855 formation of dopamine-induced intracellular bodies within striatal neurons

A rapid method for 858 assessing the distribution of gold labeling on thin sections

A549 or Huh-7 cells were seeded in 96-CellCarrierUltra plates (Perkin Elmer, Hamburg, 665Germany), then infected or treated as described above. Cells were fixed using 3.7% formaldehyde 666 and stained with the following primary antibodies: anti-NAAA (1:300, Abnova, Taipei Huh-7 cells were infected or treated as described above. Then, cells were fixed with 2.0% 684 paraformaldehyde/0.1% glutaraldehyde, both dissolved in 0.1 M PBS pH 7.4 for 90 min at 4 °C. 685Cells were gently scraped from the plate, collected into vials, and centrifuged at 10,000 rpm for 686 10 min. cells were then resuspended in PBS and post-fixed in 1% osmium tetroxide (OsO4 ) for 687 1 h at 4 °C. Then, the post-fixed pellet was dehydrated in a gradient of ethanol solutions 50%, 688 70%, 90%, and 95%, each for 5 min, to reach 100% ethanol for 60 min. Finally, the pellet was 689